PE20091107A1 - Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas - Google Patents

Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas

Info

Publication number: PE20091107A1
Authority: PE; Peru
Prior art keywords: diona; dihydroxy; prop; tetramethyl; epotilones
Prior art date: 2007-12-10

Application number

PE2008002025A

Other languages

English (en)

Spanish (es)

Inventor

Katrin Fischer

Sascha General

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-10

Filing date

2008-12-09

Publication date

2009-08-29

2008-12-09 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2009-08-29 Publication of PE20091107A1 publication Critical patent/PE20091107A1/es

Links

239000002105 nanoparticle Substances 0.000 title abstract 4
229920000642 polymer Polymers 0.000 title abstract 2
239000007787 solid Substances 0.000 title 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract 1
229920000615 alginic acid Polymers 0.000 abstract 1
229960001126 alginic acid Drugs 0.000 abstract 1
235000010443 alginic acid Nutrition 0.000 abstract 1
239000000783 alginic acid Substances 0.000 abstract 1
150000004781 alginic acids Chemical class 0.000 abstract 1
229920006317 cationic polymer Polymers 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940039227 diagnostic agent Drugs 0.000 abstract 1
239000000032 diagnostic agent Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000012874 electrostatic modification Methods 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920000728 polyester Polymers 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
229920002635 polyurethane Polymers 0.000 abstract 1
239000004814 polyurethane Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nanotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PE2008002025A 2007-12-10 2008-12-09 Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas PE20091107A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102007059752A DE102007059752A1 (de)	2007-12-10	2007-12-10	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone

Publications (1)

Publication Number	Publication Date
PE20091107A1 true PE20091107A1 (es)	2009-08-29

Family

ID=40409013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2008002025A PE20091107A1 (es)	2007-12-10	2008-12-09	Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas

Country Status (7)

Country	Link
AR (1)	AR069638A1 (fr)
DE (1)	DE102007059752A1 (fr)
PA (1)	PA8806901A1 (fr)
PE (1)	PE20091107A1 (fr)
TW (1)	TW200932220A (fr)
UY (1)	UY31521A1 (fr)
WO (1)	WO2009074274A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2462090T5 (es)	2008-06-16	2017-07-12	Pfizer Inc.	Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
US8613951B2 (en)	2008-06-16	2013-12-24	Bind Therapeutics, Inc.	Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
ES2721850T3 (es)	2008-06-16	2019-08-05	Pfizer	Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
WO2010068866A2 (fr)	2008-12-12	2010-06-17	Bind Biosciences	Particules thérapeutiques pour administration parentérale, et procédés de fabrication et d'utilisation associés
JP2012512175A (ja)	2008-12-15	2012-05-31	バインドバイオサイエンシズインコーポレイテッド	治療薬を徐放するための長時間循環性ナノ粒子
CN102361636A (zh) *	2009-03-03	2012-02-22	公立大学法人横浜市立大学	氨基酸接合氰基丙烯酸酯聚合物粒子
ES2721898T3 (es)	2009-12-11	2019-08-06	Pfizer	Formulaciones estables para liofilizar partículas terapéuticas
EP2515942B1 (fr)	2009-12-15	2020-02-12	Pfizer Inc.	Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés
WO2011084521A2 (fr) *	2009-12-15	2011-07-14	Bind Biosciences, Inc.	Nanoparticules polymères thérapeutiques comportant de l'épothilone et leurs procédés de fabrication et d'utilisation
CA2799202C (fr)	2010-05-18	2016-07-05	Cerulean Pharma Inc.	Compositions et procedes de traitement de maladies auto-immunes et autres
WO2012026608A1 (fr) *	2010-08-24	2012-03-01	Canon Kabushiki Kaisha	Particule polymère et colorant hydrophile ayant un groupe sulfonate encapsulé dans la particule
DK2895156T3 (da)	2012-09-17	2019-07-15	Pfizer	Fremgangsmåde til fremstilling af terapeutiske nanopartikler
JP6564369B2 (ja)	2013-12-09	2019-08-21	デュレクトコーポレイション	薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
SI3116547T1 (sl)	2014-03-14	2019-08-30	Pfizer, Inc.	Terapevtski nanodelci, ki obsegajo terapevtsko stredstvo, in postopek izdelave ter uporabe le-teh
WO2015181346A1 (fr) *	2014-05-30	2015-12-03	AbbVie Deutschland GmbH & Co. KG	Nanocapsules de poly(2-cyanoacrylate d'alkyle) hautement chargées en médicament
DE102017100317A1 (de)	2017-01-10	2018-07-12	Friedrich-Schiller-Universität Jena	Nanostrukturiertes Trägersystem zum Gentransport
CN115078292B (zh) *	2021-03-10	2025-02-11	北京大学	一种水性超分子粘附材料及其制备方法
CN119768461A (zh) *	2022-08-22	2025-04-04	爱克发-格法特公司	近红外和红光吸收复合树脂颗粒

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US262030A (en)		1882-08-01		Wash-stand
US252028A (en)		1882-01-10		Alonzo s
US258286A (en)		1882-05-23		Fruit-drier
US4774339A (en)	1987-08-10	1988-09-27	Molecular Probes, Inc.	Chemically reactive dipyrrometheneboron difluoride dyes
CA2032169A1 (fr) *	1989-05-04	1990-11-05	Steven Kornguth	Methode de localisation et de traitement des tumeurs et complexes servant a cette fin
US5366860A (en)	1989-09-29	1994-11-22	Applied Biosystems, Inc.	Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5433896A (en)	1994-05-20	1995-07-18	Molecular Probes, Inc.	Dibenzopyrrometheneboron difluoride dyes
US5227487A (en)	1990-04-16	1993-07-13	Molecular Probes, Inc.	Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5274113A (en)	1991-11-01	1993-12-28	Molecular Probes, Inc.	Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5248782A (en)	1990-12-18	1993-09-28	Molecular Probes, Inc.	Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en)	1991-05-22	1993-02-16	Molecular Probes, Inc.	Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2684103B1 (fr)	1991-11-22	1994-09-02	Centre Nat Rech Scient	Nouveaux composes a structure guanidique et composition pharmaceutique les contenant.
DE4445065A1 (de)	1994-12-07	1996-06-13	Diagnostikforschung Inst	Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
JP4183099B2 (ja)	1995-11-17	2008-11-19	ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃおよびｄ、製造法ならびに組成物
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19728914A1 (de)	1997-07-07	1999-01-14	Basf Ag	Metallisch gefärbte Polyamide
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
WO1999007692A2 (fr)	1997-08-09	1999-02-18	Schering Aktiengesellschaft	Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique
WO1999018934A1 (fr) *	1997-10-09	1999-04-22	Vanderbilt University	Dispositif d'administration de microparticules ou de nanoparticules de polymeres
US6320045B1 (en)	1997-12-04	2001-11-20	Bristol-Myers Squibb Company	Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19820599A1 (de)	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
AU4775299A (en)	1998-06-22	2000-01-10	Nicolaou, Kyriacos Costa	Desmethyl epothilones
SE517641C2 (sv)	1998-07-02	2002-07-02	Sca Hygiene Prod Ab	Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
JP2000095758A (ja)	1998-09-18	2000-04-04	Schering Ag	近赤外蛍光造影剤および蛍光造影方法
EP1140944B1 (fr)	1998-12-22	2003-08-27	Novartis AG	Derives d'epothilone et leur utilisation comme agents antitumoraux
DE19908763A1 (de)	1999-02-18	2000-08-24	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908760A1 (de)	1999-02-18	2000-08-24	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
SK11852001A3 (sk)	1999-02-18	2002-04-04	Schering Aktiengesellschaft	Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie
DE19907588A1 (de)	1999-02-22	2000-08-24	Biotechnolog Forschung Gmbh	C-21 Modifizierte Epothilone
IL144590A0 (en)	1999-03-29	2002-05-23	Bristol Myers Squibb Co	A process for the preparation of epothilone derivatives
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
CA2425620A1 (fr)	1999-10-08	2001-04-19	The Scripps Research Institute	Derives d'epothilone d'alkyle-13 inferieur
EP1259490A2 (fr)	2000-03-01	2002-11-27	Sloan Kettering Institute For Cancer Research	Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
DE10020517A1 (de)	2000-04-19	2001-10-25	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020045609A1 (en)	2000-05-26	2002-04-18	Gary Ashley	Epothilone derivatives and methods for making and using the same
US20020137152A1 (en)	2000-07-25	2002-09-26	Daniel Santi	Fermentation process for epothilones
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2425828A1 (fr)	2000-10-13	2002-04-18	The University Of Mississippi	Synthese d'epothilones et d'analogues associes
ATE349412T1 (de)	2000-10-16	2007-01-15	R & D Biopharmaceuticals	Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
WO2002080846A2 (fr)	2001-04-03	2002-10-17	Kosan Biosciences, Inc.	Derives d'epothilone : procedes de fabrication et methodes d'utilisation associes
DE102005041860A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
JP2009539793A (ja) *	2006-06-08	2009-11-19	バイエル・シエーリング・ファーマアクチエンゲゼルシャフト	診断及び治療用途のための官能化された固体ポリマーナノ粒子

2007
- 2007-12-10 DE DE102007059752A patent/DE102007059752A1/de not_active Withdrawn
2008
- 2008-12-06 WO PCT/EP2008/010371 patent/WO2009074274A1/fr not_active Ceased
- 2008-12-09 TW TW097147937A patent/TW200932220A/zh unknown
- 2008-12-09 UY UY31521A patent/UY31521A1/es not_active Application Discontinuation
- 2008-12-09 PA PA20088806901A patent/PA8806901A1/es unknown
- 2008-12-09 PE PE2008002025A patent/PE20091107A1/es not_active Application Discontinuation
- 2008-12-10 AR ARP080105366A patent/AR069638A1/es unknown

Also Published As

Publication number	Publication date
UY31521A1 (es)	2009-08-03
TW200932220A (en)	2009-08-01
DE102007059752A1 (de)	2009-06-18
WO2009074274A1 (fr)	2009-06-18
PA8806901A1 (es)	2009-07-23
AR069638A1 (es)	2010-02-10

Publication	Publication Date	Title
PE20091107A1 (es)	2009-08-29	Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas
Murugesan et al.	2021	Chitosan‐based nanocomposites for medical applications
Gowda et al.	2022	Stimuli-responsive microneedles as a transdermal drug delivery system: a demand-supply strategy
Ayoubi‐Joshaghani et al.	2020	Potential applications of advanced nano/hydrogels in biomedicine: static, dynamic, multi‐stage, and bioinspired
Zahid et al.	2022	Leveraging the advancements in functional biomaterials and scaffold fabrication technologies for chronic wound healing applications
Doraiswamy et al.	2006	Two photon induced polymerization of organic–inorganic hybrid biomaterials for microstructured medical devices
Ma et al.	2017	Mesoporous silica as micro/nano-carrier: From passive to active cargo delivery, a mini review
Razatos et al.	2000	Force measurements between bacteria and poly (ethylene glycol)-coated surfaces
Korkmaz et al.	2015	Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays
Hou et al.	2011	Microtopographic patterns affect Escherichia coli biofilm formation on poly (dimethylsiloxane) surfaces
EP3548135B1 (fr)	2021-10-13	Dispositifs à micro-aiguilles coeur-enveloppe et leurs utilisations
AR117389A2 (es)	2021-08-04	Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer
BRPI0905752A2 (pt)	2015-12-01	"muteína de lipocalina da lágrima humana (htlc), molécula de ácido nucléico, célula hospedeira, composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana, método de tratamento de uma doença ou distúrbio e uso de uma mateína de lipocalina da lágrima humana"
Massaro et al.	2018	Multifunctional carrier based on halloysite/laponite hybrid hydrogel for kartogenin delivery
WO2010123945A3 (fr)	2011-04-21	Hydrogels à base de fibroïnes de soie et leurs utilisations
Yang et al.	2024	Intra‐articular injection of nanomaterials for the treatment of osteoarthritis: from lubrication function restoration to cell and gene therapy
Barthes et al.	2012	Stretch-induced biodegradation of polyelectrolyte multilayer films for drug release
Chen et al.	2014	Robust, flexible, and bioadhesive free-standing films for the co-delivery of antibiotics and growth factors
Majcher et al.	2019	Applications of hydrogels
Seo et al.	2018	Diatom microbubbler for active biofilm removal in confined spaces
WO2008085556A3 (fr)	2008-10-16	Nanoparticules sans agent tensioactif pour administration de médicaments
Zhou et al.	2023	Dynamic and wearable electro-responsive hydrogel with robust mechanical properties for drug release
Pepelanova	2021	Tunable hydrogels: introduction to the world of smart materials for biomedical applications
Phoungtawee et al.	2021	Polymers with hemiaminal ether linkages for pH-responsive antibacterial materials
Yu et al.	2019	β-Lactamase responsive supramolecular hydrogels with host–guest self-healing capability

Legal Events

Date	Code	Title	Description
2010-03-08	FA	Abandonment or withdrawal